CA1087985A - Glycosides cardiaques en preparation pharmaceutique facilement absorbee au niveau de l'intestin et methode de preparation - Google Patents

Glycosides cardiaques en preparation pharmaceutique facilement absorbee au niveau de l'intestin et methode de preparation

Info

Publication number: CA1087985A
Authority: CA; Canada
Prior art keywords: composition; cardiac glycoside; mixture; strophanthin; chain length
Prior art date: 1976-07-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA282,536A

Other languages

English (en)

Inventor

Theodor Eckert

Fritz H. Kemper

Martin Wischniewski

Reinhard Hempel

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Abbott Products GmbH

Original Assignee

Kali Chemie Pharma GmbH

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1976-07-12

Filing date

1977-07-12

Publication date

1980-10-21

1976-07-12 Priority claimed from DE19762631281 external-priority patent/DE2631281A1/de

1976-11-18 Priority claimed from DE19762652508 external-priority patent/DE2652508A1/de

1976-12-01 Priority claimed from DE19762654386 external-priority patent/DE2654386A1/de

1976-12-03 Priority claimed from DE19762654844 external-priority patent/DE2654844A1/de

1977-07-12 Application filed by Kali Chemie Pharma GmbH filed Critical Kali Chemie Pharma GmbH

1980-10-21 Application granted granted Critical

1980-10-21 Publication of CA1087985A publication Critical patent/CA1087985A/fr

Status Expired legal-status Critical Current

Links

229940097217 cardiac glycoside Drugs 0.000 title abstract description 45
239000002368 cardiac glycoside Substances 0.000 title abstract description 45
229930002534 steroid glycoside Natural products 0.000 title abstract description 45
150000008143 steroidal glycosides Chemical group 0.000 title abstract description 35
238000002360 preparation method Methods 0.000 title abstract description 22
239000008194 pharmaceutical composition Substances 0.000 title abstract description 7
LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 abstract description 38
125000005456 glyceride group Chemical group 0.000 abstract description 30
LPMXVESGRSUGHW-UHFFFAOYSA-N Acolongiflorosid K Natural products OC1C(O)C(O)C(C)OC1OC1CC2(O)CCC3C4(O)CCC(C=5COC(=O)C=5)C4(C)CC(O)C3C2(CO)C(O)C1 LPMXVESGRSUGHW-UHFFFAOYSA-N 0.000 abstract description 29
229960003343 ouabain Drugs 0.000 abstract description 28
FHIREUBIEIPPMC-UHFFFAOYSA-N K-Strophanthin-beta Natural products O1C(C)C(OC2C(C(O)C(O)C(CO)O2)O)C(OC)CC1OC(CC1(O)CCC2C3(O)CC4)CCC1(C=O)C2CCC3(C)C4C1=CC(=O)OC1 FHIREUBIEIPPMC-UHFFFAOYSA-N 0.000 abstract description 15
MYEJFUXQJGHEQK-ALRJYLEOSA-N Proscillaridin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C=C2CC[C@H]3[C@@]4(O)CC[C@H](C5=COC(=O)C=C5)[C@@]4(C)CC[C@@H]3[C@@]2(C)CC1 MYEJFUXQJGHEQK-ALRJYLEOSA-N 0.000 abstract description 15
235000014113 dietary fatty acids Nutrition 0.000 abstract description 15
239000000194 fatty acid Substances 0.000 abstract description 15
229930195729 fatty acid Natural products 0.000 abstract description 15
150000004665 fatty acids Chemical class 0.000 abstract description 15
229930190098 proscillaridin Natural products 0.000 abstract description 15
229960003584 proscillaridin Drugs 0.000 abstract description 15
MYEJFUXQJGHEQK-UHFFFAOYSA-N proscillaridin A Natural products OC1C(O)C(O)C(C)OC1OC1C=C2CCC3C4(O)CCC(C5=COC(=O)C=C5)C4(C)CCC3C2(C)CC1 MYEJFUXQJGHEQK-UHFFFAOYSA-N 0.000 abstract description 15
GILGYKHFZXQALF-UHFFFAOYSA-N k-Strophantylside Natural products O1C(C)C(OC2C(C(O)C(O)C(COC3C(C(O)C(O)C(CO)O3)O)O2)O)C(OC)CC1OC(CC1(O)CCC2C3(O)CC4)CCC1(C=O)C2CCC3(C)C4C1=CC(=O)OC1 GILGYKHFZXQALF-UHFFFAOYSA-N 0.000 abstract description 13
239000000203 mixture Substances 0.000 description 86
WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 31
238000010521 absorption reaction Methods 0.000 description 27
239000002775 capsule Substances 0.000 description 26
GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 20
238000013019 agitation Methods 0.000 description 20
239000013065 commercial product Substances 0.000 description 18
229930182470 glycoside Natural products 0.000 description 16
150000002338 glycosides Chemical class 0.000 description 15
239000007903 gelatin capsule Substances 0.000 description 13
239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 11
229960002446 octanoic acid Drugs 0.000 description 11
239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 10
239000004480 active ingredient Substances 0.000 description 9
239000000243 solution Substances 0.000 description 9
239000000829 suppository Substances 0.000 description 9
GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 8
238000009472 formulation Methods 0.000 description 7
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 6
238000000034 method Methods 0.000 description 6
239000000047 product Substances 0.000 description 6
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 6
235000012239 silicon dioxide Nutrition 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
239000013543 active substance Substances 0.000 description 5
-1 squill glycosides Chemical class 0.000 description 5
239000000725 suspension Substances 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
235000021355 Stearic acid Nutrition 0.000 description 4
239000002253 acid Substances 0.000 description 4
239000000654 additive Substances 0.000 description 4
OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 4
125000004432 carbon atom Chemical group C* 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
230000000694 effects Effects 0.000 description 4
230000002708 enhancing effect Effects 0.000 description 4
125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
230000006872 improvement Effects 0.000 description 4
229910052901 montmorillonite Inorganic materials 0.000 description 4
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 4
239000000126 substance Substances 0.000 description 4
239000003981 vehicle Substances 0.000 description 4
229910002012 Aerosil® Inorganic materials 0.000 description 3
241000282326 Felis catus Species 0.000 description 3
235000021314 Palmitic acid Nutrition 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
125000000217 alkyl group Chemical group 0.000 description 3
230000036765 blood level Effects 0.000 description 3
230000003177 cardiotonic effect Effects 0.000 description 3
239000002702 enteric coating Substances 0.000 description 3
238000009505 enteric coating Methods 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
150000002500 ions Chemical class 0.000 description 3
RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 description 3
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 3
229920006395 saturated elastomer Polymers 0.000 description 3
239000008117 stearic acid Substances 0.000 description 3
239000002511 suppository base Substances 0.000 description 3
239000003826 tablet Substances 0.000 description 3
DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 3
150000003626 triacylglycerols Chemical class 0.000 description 3
235000021122 unsaturated fatty acids Nutrition 0.000 description 3
150000004670 unsaturated fatty acids Chemical class 0.000 description 3
CTNPHHZPAJYPFO-PDXBGNJTSA-N (3s,5s,8r,9s,10s,13r,14s,17r)-3-[(2r,4s,5r,6r)-5-[(2r,3s,4s,5r,6s)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-4-methoxy-6-methyloxan-2-yl]oxy-5,14-dihydroxy-13-methyl-17-(5-oxo-2h-furan Chemical compound C1([C@@H]2[C@@]3(C)CC[C@@H]4[C@@]5(C=O)CC[C@@H](C[C@@]5(O)CC[C@H]4[C@@]3(O)CC2)O[C@H]2C[C@@H]([C@@H]([C@@H](C)O2)O[C@@H]2[C@H]([C@H](O)[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)[C@H](CO)O2)O)OC)=CC(=O)OC1 CTNPHHZPAJYPFO-PDXBGNJTSA-N 0.000 description 2
LKUNXBRZDFMZOK-GFCCVEGCSA-N Capric acid monoglyceride Natural products CCCCCCCCCC(=O)OC[C@H](O)CO LKUNXBRZDFMZOK-GFCCVEGCSA-N 0.000 description 2
244000304921 Charybdis maritima Species 0.000 description 2
240000001879 Digitalis lutea Species 0.000 description 2
WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 2
LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
ODJLBQGVINUMMR-UHFFFAOYSA-N Strophanthidin Natural products CC12CCC(C3(CCC(O)CC3(O)CC3)C=O)C3C1(O)CCC2C1=CC(=O)OC1 ODJLBQGVINUMMR-UHFFFAOYSA-N 0.000 description 2
244000166550 Strophanthus gratus Species 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
235000013871 bee wax Nutrition 0.000 description 2
239000012166 beeswax Substances 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N beta-monoglyceryl stearate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
239000000084 colloidal system Substances 0.000 description 2
GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 2
229960000648 digitoxin Drugs 0.000 description 2
WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 2
229960005156 digoxin Drugs 0.000 description 2
LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 2
LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 2
238000011049 filling Methods 0.000 description 2
239000000499 gel Substances 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
230000002107 myocardial effect Effects 0.000 description 2
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
230000000704 physical effect Effects 0.000 description 2
NXJOCELNFPGKIV-ARHXXGKOSA-N scillaren A Chemical compound C=1([C@@H]2[C@@]3(C)CC[C@@H]4[C@@]5(C)CC[C@@H](C=C5CC[C@H]4[C@@]3(O)CC2)O[C@@H]2O[C@H]([C@@H]([C@@H](O)[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)C=CC(=O)OC=1 NXJOCELNFPGKIV-ARHXXGKOSA-N 0.000 description 2
239000006104 solid solution Substances 0.000 description 2
239000012177 spermaceti Substances 0.000 description 2
229940084106 spermaceti Drugs 0.000 description 2
229940082656 strophanthus glycosides used in cardiac therapy Drugs 0.000 description 2
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
241000459479 Capsula Species 0.000 description 1
206010007559 Cardiac failure congestive Diseases 0.000 description 1
241000700198 Cavia Species 0.000 description 1
241000905957 Channa melasoma Species 0.000 description 1
241001212789 Dynamis Species 0.000 description 1
ZNDMLUUNNNHNKC-UHFFFAOYSA-N G-strophanthidin Natural products CC12CCC(C3(CCC(O)CC3(O)CC3)CO)C3C1(O)CCC2C1=CC(=O)OC1 ZNDMLUUNNNHNKC-UHFFFAOYSA-N 0.000 description 1
OCEDEAQHBIGPTE-UHFFFAOYSA-N Gitoxin Natural products CC1OC(CC(O)C1O)OC2C(O)CC(OC3C(O)CC(OC4CCC5(C)C(CCC6C5CCC7(C)C(C(O)CC67O)C8=CCOC8=O)C4)OC3C)OC2C OCEDEAQHBIGPTE-UHFFFAOYSA-N 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
229930187860 Lanatosid Natural products 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
241001163743 Perlodes Species 0.000 description 1
229920001273 Polyhydroxy acid Polymers 0.000 description 1
229930187443 Scillaren Natural products 0.000 description 1
NXJOCELNFPGKIV-NIHBEWDJSA-N Scillaren A Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@@H](O[C@@H]2C=C3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=COC(=O)C=C6)CC5)CC4)CC3)CC2)O[C@@H]1C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 NXJOCELNFPGKIV-NIHBEWDJSA-N 0.000 description 1
208000010513 Stupor Diseases 0.000 description 1
241000011102 Thera Species 0.000 description 1
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
125000005210 alkyl ammonium group Chemical group 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
235000012216 bentonite Nutrition 0.000 description 1
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
125000001589 carboacyl group Chemical group 0.000 description 1
239000000496 cardiotonic agent Substances 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
239000004927 clay Substances 0.000 description 1
230000008602 contraction Effects 0.000 description 1
239000012059 conventional drug carrier Substances 0.000 description 1
238000001816 cooling Methods 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
238000006356 dehydrogenation reaction Methods 0.000 description 1
238000009795 derivation Methods 0.000 description 1
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
229940082657 digitalis glycosides Drugs 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
238000006266 etherification reaction Methods 0.000 description 1
150000002191 fatty alcohols Chemical class 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
229950000974 gitoxin Drugs 0.000 description 1
LKRDZKPBAOKJBT-CNPIRKNPSA-N gitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(C[C@H](O)[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LKRDZKPBAOKJBT-CNPIRKNPSA-N 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
150000002402 hexoses Chemical group 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
230000033444 hydroxylation Effects 0.000 description 1
238000005805 hydroxylation reaction Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
231100000636 lethal dose Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
235000010935 mono and diglycerides of fatty acids Nutrition 0.000 description 1
150000002763 monocarboxylic acids Chemical class 0.000 description 1
238000000465 moulding Methods 0.000 description 1
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
235000021313 oleic acid Nutrition 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
229940082663 other cardiac glycosides in atc Drugs 0.000 description 1
BXSABLKMKAINIU-QOHCMMFCSA-N ouabagenin Chemical compound C1([C@H]2CC[C@]3(O)[C@H]4[C@@H]([C@]5([C@H](O)C[C@H](O)C[C@@]5(O)CC4)CO)[C@H](O)C[C@@]32C)=CC(=O)OC1 BXSABLKMKAINIU-QOHCMMFCSA-N 0.000 description 1
150000002972 pentoses Chemical class 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
229930190842 purpurea glycoside Natural products 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
ODJLBQGVINUMMR-HZXDTFASSA-N strophanthidin Chemical compound C1([C@H]2CC[C@]3(O)[C@H]4[C@@H]([C@]5(CC[C@H](O)C[C@@]5(O)CC4)C=O)CC[C@@]32C)=CC(=O)OC1 ODJLBQGVINUMMR-HZXDTFASSA-N 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000012085 test solution Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
150000005621 tetraalkylammonium salts Chemical class 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
230000008719 thickening Effects 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000820 toxicity test Toxicity 0.000 description 1
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
239000001993 wax Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Oil, Petroleum & Natural Gas (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

CA282,536A 1976-07-12 1977-07-12 Glycosides cardiaques en preparation pharmaceutique facilement absorbee au niveau de l'intestin et methode de preparation Expired CA1087985A (fr)

Applications Claiming Priority (8)

Application Number	Priority Date	Filing Date	Title
DE19762631281 DE2631281A1 (de)	1976-07-12	1976-07-12	Verfahren zur erhoehung der loeslichkeit von schwerloeslichen arzneistoffen zum zwecke deren applikation in gelatinekapseln
DEP2631281.2		1976-07-12
DE19762652508 DE2652508A1 (de)	1976-11-18	1976-11-18	Oral zu verabreichende arzneimittel
DEP2652508.6		1976-11-18
DE19762654386 DE2654386A1 (de)	1976-12-01	1976-12-01	Verfahren zur herstellung einer fuellmasse aus mono- und diglyceriden mittelkettiger fettsaeuren zum zwecke deren verarbeitung in gelatinekapseln
DEP2654386.2		1976-12-01
DEP2654844.7		1976-12-03
DE19762654844 DE2654844A1 (de)	1976-12-03	1976-12-03	Verfahren zur herstellung fester loesungen von arzneistoffen zur oralen und rektalen applikation

Publications (1)

Publication Number	Publication Date
CA1087985A true CA1087985A (fr)	1980-10-21

Family

ID=27432128

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA282,536A Expired CA1087985A (fr)	1976-07-12	1977-07-12	Glycosides cardiaques en preparation pharmaceutique facilement absorbee au niveau de l'intestin et methode de preparation

Country Status (5)

Country	Link
CA (1)	CA1087985A (fr)
GB (1)	GB1544576A (fr)
IE (1)	IE45448B1 (fr)
IL (1)	IL52472A (fr)
NZ (1)	NZ184612A (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR880012221A (ko) *	1987-04-13	1988-11-26	사노 가즈오	에스테르 또는 아미드를 활성성분으로 함유하는 약제 조성물
ITMI20070084A1 (it) *	2007-01-22	2008-07-23	Carlo Ghisalberti	Dispositivi antisettici vaginali a base lipidica

1977
- 1977-07-04 GB GB2798577A patent/GB1544576A/en not_active Expired
- 1977-07-04 IE IE137977A patent/IE45448B1/en unknown
- 1977-07-06 IL IL5247277A patent/IL52472A/xx unknown
- 1977-07-11 NZ NZ18461277A patent/NZ184612A/xx unknown
- 1977-07-12 CA CA282,536A patent/CA1087985A/fr not_active Expired

Also Published As

Publication number	Publication date
IE45448L (en)	1978-01-12
IE45448B1 (en)	1982-08-25
NZ184612A (en)	1978-12-18
GB1544576A (en)	1979-04-19
IL52472A (en)	1980-11-30

Legal Events

Date	Code	Title	Description
1997-10-21	MKEX	Expiry

Publication	Publication Date	Title
US4202888A (en)	1980-05-13	Readily enterally absorbable pharmaceutical compositions of cardiac glycosides and preparation thereof
US4722941A (en)	1988-02-02	Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
JP5592905B2 (ja)	2014-09-17	α−ヒドロキシ酸エステル薬剤送達組成物及び使用方法
JP2012006931A (ja)	2012-01-12	疎水性治療剤の改善された送達のための組成物および方法
JP4209467B2 (ja)	2009-01-14	経口投与用製剤組成物
NO844144L (no)	1985-04-29	Legemiddeltilberedning
US5028600A (en)	1991-07-02	Novel pharmaceutical composition
CN102892411B (zh)	2015-01-21	含有合成的低聚糖的药物口服剂型
KR102771577B1 (ko)	2025-02-20	3α-에티닐-3β-하이드록시안드로스탄-17-온 옥심의 약학적 제형
BR112012015016B1 (pt)	2021-05-11	Formulação farmacêutica, forma de dosagem farmacêutica entérica e uso de uma formulação
KR910000163A (ko)	1991-01-29	고형 약학제제 및 이의 제조방법
EP0302370A1 (fr)	1989-02-08	Formulations d'erythromycine pour l'administration orale
CA1087985A (fr)	1980-10-21	Glycosides cardiaques en preparation pharmaceutique facilement absorbee au niveau de l'intestin et methode de preparation
JPS63406B2 (fr)	1988-01-07
WO2006107357A1 (fr)	2006-10-12	Formulations ameliorees de fenofibrate contenant du menthol ou un melange peg/poloxamere
JPH0518806B2 (fr)	1993-03-15
GB1600639A (en)	1981-10-21	Medicament preparation having resorption properties and method of producing the same
KR810000901B1 (ko)	1981-08-19	카디아크 글리코사이드의 제제방법
JPS621925B2 (fr)	1987-01-16
RU2779262C2 (ru)	2022-09-05	ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ 3α-ЭТИНИЛ-3β-ГИДРОКСИАНДРОСТАН-17-ОНА ОКСИМА
KR20010075144A (ko)	2001-08-09	활성형 글리시리진의 생체이용률을 높이기 위한경구투여용 약물송달시스템
JPH0532627A (ja)	1993-02-09	筋肉痙攣により帰因するか又は筋肉痙攣の結果である疾病及び症候群を治療するための医薬品及びその製法
JPH0233010B2 (fr)	1990-07-25
CN111358754A (zh)	2020-07-03	一种大环内酯类抗生素长循环乳剂及其制备方法
JPS634803B2 (fr)	1988-02-01